Therapeutic uses of modified FGF-21 polypeptides

Patent metadata

Field	Value
Publication number	US-10189883-B2
Application number	US-201715460917-A
Country	US
Kind code	B2
Filing date	Mar 16, 2017
Priority date	Oct 24, 2014
Publication date	Jan 29, 2019
Grant date	Jan 29, 2019

Abstract

Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.

First claim

What is claimed is:

1. A method of decreasing or inhibiting fibrosis in a patient in need thereof, comprising administering to the patient an effective amount of a modified FGF-21 polypeptide comprising a polypeptide having at least 96% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 202.

2. The method of claim 1 , wherein said modified FGF-21 polypeptide comprises a polypeptide having at least 97% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 202.

3. The method of claim 1 , wherein said modified FGF-21 polypeptide comprises a polypeptide having at least 98% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 202.

4. The method of claim 1 , wherein said modified FGF-21 polypeptide comprises a polypeptide having at least 99% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 202.

5. The method of claim 1 , wherein said modified FGF-21 polypeptide comprises a polypeptide having the amino acid sequence of SEQ ID NO: 202.

6. The method of claim 1 , wherein said modified FGF-21 polypeptide is linked to a half-life extending moiety.

7. The method of claim 6 , wherein said half-life extending moiety comprises a poly(ethylene glycol).

8. The method of claim 7 , wherein said poly(ethylene glycol) has an average molecular weight between 10 kDa and 40 kDa.

9. The method of claim 8 , wherein said poly(ethylene glycol) has an average molecular weight of about 30 kDa.

10. The method of claim 6 , wherein said modified FGF-21 polypeptide is linked to a half-life extending moiety via a para-acetyl-L-phenylalanine in the modified FGF-21 polypeptide.

11. The method of claim 1 , wherein said method treats a disease selected from NASH, liver fibrosis, cirrhosis, diabetic kidney disease, chronic kidney disease, renal fibrosis, lung fibrosis, cardiac fibrosis, heart failure, or metabolic heart failure in said patient.

12. The method of claim 1 , wherein said method treats a disease selected from NASH or liver fibrosis in said patient.

13. A method of decreasing or inhibiting fibrosis in a patient in need thereof, comprising administering to the patient an effective amount of a modified FGF-21 polypeptide comprising a polypeptide having the amino acid sequence of (a) SEQ ID NO:202 without the N-terminal methionine or (b) SEQ ID NO:202, wherein said modified FGF-21 polypeptide is linked to poly(ethylene glycol).

14. The method of claim 13 , wherein said poly(ethylene glycol) has an average molecular weight between 10 kDa and 40 kDa.

15. The method of claim 14 , wherein said poly(ethylene glycol) has an average molecular weight of about 30 kDa.

16. The method of claim 13 , wherein said method treats a disease selected from NASH, liver fibrosis, cirrhosis, diabetic kidney disease, chronic kidney disease, renal fibrosis, lung fibrosis, cardiac fibrosis, heart failure, or metabolic heart failure in said patient.

17. The method of claim 13 , wherein said method treats a disease selected from NASH or liver fibrosis in said patient.

18. The method of claim 13 , further comprising the administration of at least one other active agent to said patient.

19. A method of reducing the incidence of or treating NASH in a patient in need thereof, comprising administering to the patient an effective amount of a modified FGF-21 polypeptide comprising a polypeptide having the amino acid sequence of SEQ ID NO:202, wherein said modified FGF-21 polypeptide is linked to poly(ethylene glycol).

20. The method of claim 19 , wherein said poly(ethylene glycol) has an average molecular weight of about 30 kDa.

Assignees

• Bristol Myers Squibb Co

Inventors

• Morin Paul E
• Cohen Daniel
• Mukherjee Ranjan
• Reilly Timothy P
• Christian Rose C
• Lipovsek Dasa
• Camphausen Ray
• Krupinski John

Classifications

• A61P9/04

  Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title

• A61P5/28

  Antiandrogens · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P3/06

  Antihyperlipidemics · CPC title